Plain-English translation of NCT05485766 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Triple Negative Breast Neoplasms research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether plus works well when given before and after surgery for a specific type of breast cancer called triple-negative breast cancer in patients with inherited BRCA mutations. You would first receive chemotherapy combined with , then switch to plus before your surgery, and continue this medication combination after surgery to help prevent the cancer from coming back.
Triple-negative breast cancer is harder to treat than other breast cancers, and people with BRCA mutations face higher risks. Researchers want to see if this new two-drug combination can improve outcomes when added to standard chemotherapy, especially before and after surgery.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy combined with for 4 cycles (about 12 weeks), then switch to plus for another 4 cycles before undergoing surgery. After surgery, you would continue taking plus for up to 9 more cycles (about 27 weeks total). Throughout the trial, you would have regular visits for blood tests, scans, and check-ups to monitor how you're doing.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Japan